4//SEC Filing
Zanganeh Mahkam 4
Accession 0001507650-25-000003
CIK 0001599298other
Filed
Oct 22, 8:00 PM ET
Accepted
Oct 23, 4:06 PM ET
Size
10.3 KB
Accession
0001507650-25-000003
Insider Transaction Report
Form 4
Zanganeh Mahkam
DirectorCo-Chief Executive Officer10% Owner
Transactions
- Purchase
Common Stock
2025-10-21$18.74/sh+26,680$499,983→ 76,680 total(indirect: Immediate family member) - Award
Common Stock
2025-10-21$18.74/sh+266,808$4,999,982→ 25,724,474 total(indirect: By Trust) - Award
Common Stock
2025-10-21$18.74/sh+13,980,789$261,999,986→ 570,073,879 total(indirect: By Spouse)
Holdings
- 10,199,776(indirect: By Trust)
Common Stock
- 31,000
Common Stock
Footnotes (2)
- [F1]Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025.
- [F2]The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Documents
Issuer
Summit Therapeutics Inc.
CIK 0001599298
Entity typeother
Related Parties
1- filerCIK 0001507650
Filing Metadata
- Form type
- 4
- Filed
- Oct 22, 8:00 PM ET
- Accepted
- Oct 23, 4:06 PM ET
- Size
- 10.3 KB